Cargando…
An Early Examination of Access to Select Orphan Drugs Treating Rare Diseases in Health Insurance Exchange Plans
BACKGROUND: Patients with rare diseases often face significant health care access challenges, particularly since the number of available treatment options for rare diseases is limited. The implementation of health insurance exchanges promises improved access to health care. However, when purchasing...
Autores principales: | Robinson, Sandy W., Brantley, Kelly, Liow, Christine, Teagarden, J. Russell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441028/ https://www.ncbi.nlm.nih.gov/pubmed/25278322 http://dx.doi.org/10.18553/jmcp.2014.20.10.997 |
Ejemplares similares
-
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the Pharmacy Benefit: Implications for Health Plans, PBMs, and Providers
por: Walden, Daniel C., et al.
Publicado: (2003) -
Examination of the Evidence for Off-Label Use of Gabapentin
por: Mack, Alicia
Publicado: (2003) -
Medicare Part D: Selected Issues for Plan Sponsors, Pharmacists, and Beneficiaries in 2008
por: DePue, Ronnie, et al.
Publicado: (2008) -
Examination of Multiple Medication Use Among TRICARE Beneficiaries Aged 65 Years and Older
por: Linton, Andrea, et al.
Publicado: (2007) -
Budgetary Impact on a U.S. Health Plan Adopting Abiraterone Acetate Plus Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
por: Sorensen, Sonja, et al.
Publicado: (2013)